Efflux pump overexpression in fluoroquinolone multidrug resistance: molecular mechanisms, PK/PD implications, global epidemiology, and translational strategies
Frontiers in Pharmacology · 22.07.2026 · 17
DOI: 10.3389/fphar.2026.1897593 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 22.07.2026. Verfasst von Ahmad H Alhowail und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fluoroquinolones are a cornerstone of human antibacterial chemotherapy because they combine broad-spectrum bactericidal activity, high oral bioavailability, and excellent tissue penetration. However, their clinical utility is being eroded by the global spread of multidrug-resistant (MDR) pathogens. While quinolone resistance-determining region (QRDR) mutations in DNA gyrase and topoisomerase IV remain the primary determinants of high-level resistance, mounting evidence implicates active efflux pump overexpression as an important exposure-modifying mechanism. This mechanism can amplify multidrug resistance. This review provides a pharmacology-centered synthesis of fluoroquinolone mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) indices, and the mutant selection window (MSW) framework, and integrates these concepts with the structural and regulatory biology of efflux systems in major human ESKAPE pathogens. We highlight how resistance-nodulation-division (RND) pumps in Gram-negative bacteria (e.g., AcrAB-TolC, Mex-family systems) and major facilitator superfamily (MFS) pumps in Gram-positive cocci (e.g., NorA/NorB/NorC) lower intracellular drug exposure, widen the MSW, and promote stepwise acquisition of QRDR mutations and plasmid-mediated quinolone resistance. Using recent WHO GLASS data and health-economic analyses, we summarize global resistance trends and discuss the broader healthcare and macroeconomic burden associated with MDR bacterial infections. Finally, we discuss translational strategies to mitigate efflux-mediated resistance, including the preclinical pipeline of efflux pump inhibitors (EPIs), PK/PD-informed high-exposure dosing regimens, and One Health-aligned antimicrobial stewardship interventions. By linking molecular mechanism, PK/PD, epidemiology, and health economics, this review aims to inform rational dosing, drug development, and policy decisions needed to preserve the efficacy of this vital antimicrobial class.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah, Al Qassim, Saudi Arabia.
Zitieren
APA
Alhowail, A. H., & Almogbel, Y. S. (2026). Efflux pump overexpression in fluoroquinolone multidrug resistance: molecular mechanisms, PK/PD implications, global epidemiology, and translational strategies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1897593
Vancouver
Alhowail AH, Almogbel YS. Efflux pump overexpression in fluoroquinolone multidrug resistance: molecular mechanisms, PK/PD implications, global epidemiology, and translational strategies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1897593
BibTeX
@article{Alhowail2026,
author = {Alhowail, Ahmad H and Almogbel, Yasser S},
title = {Efflux pump overexpression in fluoroquinolone multidrug resistance: molecular mechanisms, PK/PD implications, global epidemiology, and translational strategies},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1897593}
}
EUVIMED